Gilmore O'Neill, M.B., M.M.Sc

2019

In 2019, Gilmore O'Neill, M.B., M.M.Sc earned a total compensation of $5.2M as Executive Vice President, Chief Scientific Officer at Sarepta Therapeutics, a 20% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$354,063
Option Awards$4,234,786
Salary$563,962
Other$15,300
Total$5,168,110

MMSc received $4.2M in option awards, accounting for 82% of the total pay in 2019.

MMSc also received $354.1K in non-equity incentive plan, $564K in salary and $15.3K in other compensation.

Rankings

In 2019, Gilmore O'Neill, M.B., M.M.Sc's compensation ranked 2,105th out of 13,971 executives tracked by ExecPay. In other words, MMSc earned more than 84.9% of executives.

ClassificationRankingPercentile
All
2,105
out of 13,971
85th
Division
Manufacturing
763
out of 5,692
87th
Major group
Chemicals And Allied Products
235
out of 2,189
89th
Industry group
Drugs
190
out of 1,875
90th
Industry
Pharmaceutical Preparations
137
out of 1,387
90th

Pay ratio

Gilmore O'Neill, M.B., M.M.Sc's Pay$5,168,110
Median Employee's Pay$290,714
Pay Ratio

18

to 1

In 2019, the annual total compensation of Gilmore O'Neill, M.B., M.M.Sc was $5,168,110.

The annual total compensation of the median employee at Sarepta Therapeutics was $290,714.

The ratio of Gilmore O'Neill, M.B., M.M.Sc's pay to the pay of median employee was therefore 18 to one.

Source: SEC filing on April 21, 2020.

MMSc's colleagues

We found four more compensation records of executives who worked with Gilmore O'Neill, M.B., M.M.Sc at Sarepta Therapeutics in 2019.

2019

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2019

William Ciambrone

Sarepta Therapeutics

Executive Vice President, Technical Operations

2019

David Howton

Sarepta Therapeutics

General Counsel

2019

Douglas Ingram

Sarepta Therapeutics

Chief Executive Officer

News

In-depth

You may also like